Prognostic markers for myeloid neoplasms: A comparative review of the literature and goals for future investigation

T. A. Juopperi, D. Bienzle, D. C. Bernreuter, William Vernau, M. A. Thrall, P. M. McManus

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Myeloid neoplasms include cancers associated with both rapid (acute myeloid leukemias) and gradual (myelodysplastic syndromes and myeloproliferative neoplasms) disease progression. Percentage of blast cells in marrow is used to separate acute (rapid) from chronic (gradual) and is the most consistently applied prognostic marker in veterinary medicine. However, since there is marked variation in tumor progression within groups, there is a need for more complex schemes to stratify animals into specific risk groups. In people with acute myeloid leukemia (AML), pretreatment karyotyping and molecular genetic analysis have greater utility as prognostic markers than morphologic and immunologic phenotypes. Karyotyping is not available as a prognostic marker for AML in dogs and cats, but progress in molecular genetics has created optimism about the eventual ability of veterinarians to discern conditions potentially responsive to medical intervention. In people with myelodysplastic syndromes (MDS), detailed prognostic scoring systems have been devised that use various combinations of blast cell percentage, hematocrit, platelet counts, unilineal versus multilineal cytopenias and dysplasia, karyotype, gender, age, immunophenotype, transfusion dependence, and colony-forming assays. Predictors of outcome for animals with MDS have been limited to blast cell percentage, anemia versus multilineal cytopenias, and morphologic phenotype. Prognostic markers for myeloproliferative neoplasms (eg, polycythemia vera, essential thrombocythemia) include clinical and hematological factors and in people also include cytogenetics and molecular genetics. Validation of prognostic markers for myeloid neoplasms in animals has been thwarted by the lack of a large case series that requires cooperation across institutions and veterinary specialties. Future progress requires overcoming these barriers.

Original languageEnglish (US)
Pages (from-to)182-197
Number of pages16
JournalVeterinary Pathology
Volume48
Issue number1
DOIs
StatePublished - Jan 2011

Fingerprint

myeloid leukemia
neoplasms
Myelodysplastic Syndromes
Acute Myeloid Leukemia
molecular genetics
karyotyping
Molecular Biology
Karyotyping
Neoplasms
thrombocythemia
polycythemia
Phenotype
Essential Thrombocythemia
phenotype
Polycythemia Vera
animals
Aptitude
Veterinary Medicine
Veterinarians
blood platelet count

Keywords

  • Cats
  • Dogs
  • Myelodysplastic
  • Myeloid leukemia
  • Myeloproliferative neoplasms
  • Prognosis
  • Review

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Prognostic markers for myeloid neoplasms : A comparative review of the literature and goals for future investigation. / Juopperi, T. A.; Bienzle, D.; Bernreuter, D. C.; Vernau, William; Thrall, M. A.; McManus, P. M.

In: Veterinary Pathology, Vol. 48, No. 1, 01.2011, p. 182-197.

Research output: Contribution to journalArticle

Juopperi, T. A. ; Bienzle, D. ; Bernreuter, D. C. ; Vernau, William ; Thrall, M. A. ; McManus, P. M. / Prognostic markers for myeloid neoplasms : A comparative review of the literature and goals for future investigation. In: Veterinary Pathology. 2011 ; Vol. 48, No. 1. pp. 182-197.
@article{36e80701c1744a398cceb8a0b1e098d8,
title = "Prognostic markers for myeloid neoplasms: A comparative review of the literature and goals for future investigation",
abstract = "Myeloid neoplasms include cancers associated with both rapid (acute myeloid leukemias) and gradual (myelodysplastic syndromes and myeloproliferative neoplasms) disease progression. Percentage of blast cells in marrow is used to separate acute (rapid) from chronic (gradual) and is the most consistently applied prognostic marker in veterinary medicine. However, since there is marked variation in tumor progression within groups, there is a need for more complex schemes to stratify animals into specific risk groups. In people with acute myeloid leukemia (AML), pretreatment karyotyping and molecular genetic analysis have greater utility as prognostic markers than morphologic and immunologic phenotypes. Karyotyping is not available as a prognostic marker for AML in dogs and cats, but progress in molecular genetics has created optimism about the eventual ability of veterinarians to discern conditions potentially responsive to medical intervention. In people with myelodysplastic syndromes (MDS), detailed prognostic scoring systems have been devised that use various combinations of blast cell percentage, hematocrit, platelet counts, unilineal versus multilineal cytopenias and dysplasia, karyotype, gender, age, immunophenotype, transfusion dependence, and colony-forming assays. Predictors of outcome for animals with MDS have been limited to blast cell percentage, anemia versus multilineal cytopenias, and morphologic phenotype. Prognostic markers for myeloproliferative neoplasms (eg, polycythemia vera, essential thrombocythemia) include clinical and hematological factors and in people also include cytogenetics and molecular genetics. Validation of prognostic markers for myeloid neoplasms in animals has been thwarted by the lack of a large case series that requires cooperation across institutions and veterinary specialties. Future progress requires overcoming these barriers.",
keywords = "Cats, Dogs, Myelodysplastic, Myeloid leukemia, Myeloproliferative neoplasms, Prognosis, Review",
author = "Juopperi, {T. A.} and D. Bienzle and Bernreuter, {D. C.} and William Vernau and Thrall, {M. A.} and McManus, {P. M.}",
year = "2011",
month = "1",
doi = "10.1177/0300985810389317",
language = "English (US)",
volume = "48",
pages = "182--197",
journal = "Veterinary Pathology",
issn = "0300-9858",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Prognostic markers for myeloid neoplasms

T2 - A comparative review of the literature and goals for future investigation

AU - Juopperi, T. A.

AU - Bienzle, D.

AU - Bernreuter, D. C.

AU - Vernau, William

AU - Thrall, M. A.

AU - McManus, P. M.

PY - 2011/1

Y1 - 2011/1

N2 - Myeloid neoplasms include cancers associated with both rapid (acute myeloid leukemias) and gradual (myelodysplastic syndromes and myeloproliferative neoplasms) disease progression. Percentage of blast cells in marrow is used to separate acute (rapid) from chronic (gradual) and is the most consistently applied prognostic marker in veterinary medicine. However, since there is marked variation in tumor progression within groups, there is a need for more complex schemes to stratify animals into specific risk groups. In people with acute myeloid leukemia (AML), pretreatment karyotyping and molecular genetic analysis have greater utility as prognostic markers than morphologic and immunologic phenotypes. Karyotyping is not available as a prognostic marker for AML in dogs and cats, but progress in molecular genetics has created optimism about the eventual ability of veterinarians to discern conditions potentially responsive to medical intervention. In people with myelodysplastic syndromes (MDS), detailed prognostic scoring systems have been devised that use various combinations of blast cell percentage, hematocrit, platelet counts, unilineal versus multilineal cytopenias and dysplasia, karyotype, gender, age, immunophenotype, transfusion dependence, and colony-forming assays. Predictors of outcome for animals with MDS have been limited to blast cell percentage, anemia versus multilineal cytopenias, and morphologic phenotype. Prognostic markers for myeloproliferative neoplasms (eg, polycythemia vera, essential thrombocythemia) include clinical and hematological factors and in people also include cytogenetics and molecular genetics. Validation of prognostic markers for myeloid neoplasms in animals has been thwarted by the lack of a large case series that requires cooperation across institutions and veterinary specialties. Future progress requires overcoming these barriers.

AB - Myeloid neoplasms include cancers associated with both rapid (acute myeloid leukemias) and gradual (myelodysplastic syndromes and myeloproliferative neoplasms) disease progression. Percentage of blast cells in marrow is used to separate acute (rapid) from chronic (gradual) and is the most consistently applied prognostic marker in veterinary medicine. However, since there is marked variation in tumor progression within groups, there is a need for more complex schemes to stratify animals into specific risk groups. In people with acute myeloid leukemia (AML), pretreatment karyotyping and molecular genetic analysis have greater utility as prognostic markers than morphologic and immunologic phenotypes. Karyotyping is not available as a prognostic marker for AML in dogs and cats, but progress in molecular genetics has created optimism about the eventual ability of veterinarians to discern conditions potentially responsive to medical intervention. In people with myelodysplastic syndromes (MDS), detailed prognostic scoring systems have been devised that use various combinations of blast cell percentage, hematocrit, platelet counts, unilineal versus multilineal cytopenias and dysplasia, karyotype, gender, age, immunophenotype, transfusion dependence, and colony-forming assays. Predictors of outcome for animals with MDS have been limited to blast cell percentage, anemia versus multilineal cytopenias, and morphologic phenotype. Prognostic markers for myeloproliferative neoplasms (eg, polycythemia vera, essential thrombocythemia) include clinical and hematological factors and in people also include cytogenetics and molecular genetics. Validation of prognostic markers for myeloid neoplasms in animals has been thwarted by the lack of a large case series that requires cooperation across institutions and veterinary specialties. Future progress requires overcoming these barriers.

KW - Cats

KW - Dogs

KW - Myelodysplastic

KW - Myeloid leukemia

KW - Myeloproliferative neoplasms

KW - Prognosis

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=79951936407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951936407&partnerID=8YFLogxK

U2 - 10.1177/0300985810389317

DO - 10.1177/0300985810389317

M3 - Article

C2 - 21139142

AN - SCOPUS:79951936407

VL - 48

SP - 182

EP - 197

JO - Veterinary Pathology

JF - Veterinary Pathology

SN - 0300-9858

IS - 1

ER -